Trials / Recruiting
RecruitingNCT06477484
Blood Biomarkers for Screening of Alzheimer's Disease
Blood-based Biomarkers for Early Alzheimer's Disease Screening
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 180 (estimated)
- Sponsor
- Peking University First Hospital · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are: * to identify core blood biomarker suitable for early screening of AD. * to establish a comprehensive model for the early identification of AD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Blood biomarker | Blood biomarker |
Timeline
- Start date
- 2024-06-18
- Primary completion
- 2026-03-26
- Completion
- 2026-03-26
- First posted
- 2024-06-27
- Last updated
- 2024-06-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06477484. Inclusion in this directory is not an endorsement.